Fotemustine

This image is provided by the National Library of Medicine.

WikiDoc Resources for Fotemustine
Articles
Most recent articles on Fotemustine Most cited articles on Fotemustine Review articles on Fotemustine Articles on Fotemustine in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Fotemustine Images of Fotemustine Photos of Fotemustine Podcasts & MP3s on Fotemustine Videos on Fotemustine
Evidence Based Medicine
Cochrane Collaboration on Fotemustine Bandolier on Fotemustine TRIP on Fotemustine
Clinical Trials
Ongoing Trials on Fotemustine at Clinical Trials.gov Trial results on Fotemustine Clinical Trials on Fotemustine at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Fotemustine NICE Guidance on Fotemustine NHS PRODIGY Guidance FDA on Fotemustine CDC on Fotemustine
Books
Books on Fotemustine
News
Fotemustine in the news Be alerted to news on Fotemustine News trends on Fotemustine
Commentary
Blogs on Fotemustine
Definitions
Definitions of Fotemustine
Patient Resources / Community
Patient resources on Fotemustine Discussion groups on Fotemustine Patient Handouts on Fotemustine Directions to Hospitals Treating Fotemustine Risk calculators and risk factors for Fotemustine
Healthcare Provider Resources
Symptoms of Fotemustine Causes & Risk Factors for Fotemustine Diagnostic studies for Fotemustine Treatment of Fotemustine
Continuing Medical Education (CME)
CME Programs on Fotemustine
International
Fotemustine en Espanol Fotemustine en Francais
Business
Fotemustine in the Marketplace Patents on Fotemustine
Experimental / Informatics
List of terms related to Fotemustine

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Fotemustine is a nitrosourea alkylating agent approved for use in the treatment of metastasising melanoma. A study has shown that fotemustine produces improved response rates and but does not increase survival (over dacarbazine in the treatment of disseminated cutaneous melanoma. Median survival was 7.3 months with fotemustine versus 5.6 months with DTIC (P=.067). There was also toxicity prevalence in fotemustine arm. The main toxicity was grade 3 to 4 neutropenia (51% with fotemustine v 5% with DTIC) and thrombocytopenia (43% v 6%, respectively).